Hauser Bradley 4
4 · Soliton, Inc. · Filed Dec 17, 2021
Insider Transaction Report
Form 4
Soliton, Inc.SOLY
Hauser Bradley
Director
Transactions
- Disposition to Issuer
Stock option (right to buy)
2021-12-16−15,000→ 0 totalExercise: $12.94Exp: 2030-06-19→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock option (right to buy)
2021-12-16−30,000→ 0 totalExercise: $1.75Exp: 2028-06-19→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock option (right to buy)
2021-12-16−350,000→ 0 totalExercise: $7.16Exp: 2030-10-30→ Common Stock (350,000 underlying) - Disposition to Issuer
Restricted Stock Units
2021-12-16−200,000→ 0 total→ Common Stock (200,000 underlying) - Disposition to Issuer
Stock option (right to buy)
2021-12-16−15,000→ 0 totalExercise: $14.62Exp: 2029-06-27→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.
- [F2]Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding restricted stock unit, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration.